Skip to main content
. 2014 May 29;2014:709756. doi: 10.1155/2014/709756

Table 4.

HRs for all-cause and cardiovascular mortality according to different levels of TC, non-HDL-C, or TC/HDL-C.

Variables Number of deaths Person-years Hazard ratios (95% confidence intervals)
All-cause mortality CVD mortality
Total CVD Model 1a Model 2b Model 3c Model 1a Model 2b Model 3c
TC (mg/dL)
 <150 43 29 1317 1.00 1.00 1.00 1.00 1.00 1.00
 150–199 60 45 2843 0.69 (0.46–1.03) 0.71 (0.45–1.08) 0.71 (0.47–1.08) 0.76 (0.47–1.23) 0.80 (0.49–1.32) 0.81 (0.49–1.32)
 200–239 35 31 1325 1.14 (0.72–1.82) 1.29 (0.80–2.07) 1.29 (0.80–2.07) 1.54 (0.91–2.59) 1.80 (1.05–3.10) 1.79 (1.04–3.09)
 ≥240 9 8 512 0.78 (0.37–1.61) 0.82 (0.39–1.75) 0.78 (0.37–1.67) 1.05 (0.48–2.34) 1.17 (0.51–2.68) 1.14 (0.50–2.60)
P for trend 0.083 0.053 0.051 0.034 0.013 0.014
Non-HDL-C (mg/dL)
 <100 27 18 921 1.00 1.00 1.00 1.00 1.00 1.00
 100–129 45 34 1581 1.06 (0.66–1.71) 1.15 (0.71–1.88) 1.12 (0.68–1.82) 1.19 (0.67–2.11) 1.32 (0.74–2.38) 1.29 (0.72–2.32)
 130–159 32 25 1792 0.67 (0.40–1.13) 0.71 (0.41–1.21) 0.70 (0.41–1.20) 0.79 (0.43–1.46) 0.84 (0.45–1.58) 0.84 (0.45–1.58)
 160–189 32 27 1027 1.38 (0.82–2.32) 1.52 (0.89–2.59) 1.49 (0.87–2.55) 1.76 (0.96–3.22) 2.03 (1.09-3.79) 2.00 (1.08–3.74)
 ≥190 11 9 675 0.88 (0.43–1.80) 0.97 (0.47–2.02) 0.92 (0.44–1.92) 1.09 (0.48–2.45) 1.23 (0.53–2.85) 1.18 (0.51–2.73)
P for trend 0.07 0.06 0.07 0.07 0.04 0.04
TC/HDL ratio
 Quartile 1 36 27 1474 1.00 1.00 1.00 1.00 1.00 1.00
 Quartile 2 30 21 1482 0.93 (0.57–1.51) 0.93 (0.56–1.54) 0.89 (0.54–1.48) 0.86 (0.48–1.53) 0.82 (0.46–1.49) 0.80 (0.44–1.44)
 Quartile 3 34 26 1471 1.08 (0.67–1.73) 1.09 (0.67–1.78) 1.08 (0.66–1.75) 1.10 (0.64–1.89) 1.06 (0.60–1.84) 1.05 (0.60–1.83)
 Quartile 4 47 39 1570 1.62 (1.04–2.52) 1.53 (0.96–2.43) 1.53 (0.96–2.43) 1.75 (1.06–2.88) 1.56 (0.92–2.64) 1.56 (0.92–2.65)
P for trend 0.061 0.15 0.12 0.035 0.11 0.094

aModel 1 was adjusted for age, gender, education, marriage, leisure-time physical activity, smoking, and alcohol drinking.

bModel 2 was adjusted for model 1 covariates plus type, severity, duration, and treatment of CAD, history of diabetes, history of heart failure, BMI, systolic blood pressure, glomerular filtration rate, and use of antihypertensive drugs, antidiabetic drugs, and antiplatelet drugs.

cModel 3 was adjusted for model 2 covariates plus use of cholesterol-lowering drugs.